A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2026

Primary Completion Date

April 30, 2027

Study Completion Date

September 30, 2027

Conditions
NMO Spectrum DisorderSpasticity, Muscle
Interventions
DRUG

Nabiximols

Nabiximols is is a yellow-brown oromucosal spray solution containing 27 mg/mL of THC and 25 mg/mL of CBD.

DRUG

Placebo

The placebo is a matching oromucosal spray that is identical to the investigational study product in terms of packaging, labelling, schedule of administration, dosing instructions, and appearance.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Jazz Pharmaceuticals

INDUSTRY

lead

Michael, Levy M.D.,Ph.D.

OTHER